文献速递系统性红斑狼疮其他结缔组织病

新发系统性红斑狼疮血栓栓塞事件与抗磷脂综合征的累积:基于人群的起始队列研究

Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study.
PubMed 文献 · RMD Open · 2025-09-02

该研究纳入挪威东南部2000—2017年700例新发系统性红斑狼疮(SLE)患者,平均随访8年,评估血栓栓塞事件(TE)和抗磷脂综合征(APS)相对SLE发病的时间分布与发生率。结果显示13%(89/700)发生新发TE,抗磷脂抗体(aPL)阳性且诊断APS的患者SLE首年TE发生率高达59/100人年(95%CI 38至87),此后4年降至12(95%CI 6.2至21),而无APS患者相应为2.6(95%CI 1.4至4.3)和0.9(95%CI 0.5至1.4)。作者结论认为新诊断SLE患者TE风险高,尤其aPL阳性者围绕SLE诊断期风险突出,需要关注并尽早采取预防策略。

要点

  • 700例新发SLE患者平均随访8年,13%(89/700)发生新发血栓栓塞事件。
  • aPL阳性且诊断APS者SLE首年TE发生率为59/100人年(95%CI 38至87),随后4年降至12(95%CI 6.2至21)。
  • 无APS患者首年及随后4年TE发生率分别为2.6(95%CI 1.4至4.3)和0.9(95%CI 0.5至1.4)。

核心结论

  • 该基于人群的研究显示新发SLE患者血栓栓塞事件风险高,尤其aPL阳性患者在SLE诊断前后风险突出。
  • 作者认为新诊断SLE患者TE风险升高需要关注并尽早采取预防策略。

研究设计与样本

  • APS按2006年悉尼分类标准定义,aPL阳性按国际指南判定,主要结局为APS、TE和死亡,采用Kaplan-Meier法估计无结局生存率。

主要发现

  • 700例新发SLE患者平均随访8年(SD 5.0),13%(89/700)发生新发TE。
  • aPL阳性且诊断APS的患者SLE首年TE发生率为59/100人年(95%CI 38至87),随后4年降至12(95%CI 6.2至21)。
  • 无APS患者首年TE发生率为2.6/100人年(95%CI 1.4至4.3),随后4年为0.9/100人年(95%CI 0.5至1.4)。
  • aPL阴性且年龄<50岁患者TE发生率最低,1年无TE生存率为0.99(95%CI 0.97至1.0)。
  • SLE首年之后,aPL阳性与阴性患者的无TE生存率无差异;合并与不合并APS患者的标准化死亡率分别为4.7(95%CI 1.8至10.7)和1.7(95%CI 1.2至2.3)。

关键数值与推荐

  • SLE分类采用2019年欧洲抗风湿病联盟/美国风湿病学会分类标准。
  • APS定义采用2006年悉尼分类标准,aPL阳性按国际指南判定。

临床怎么用

  • 原文结论指出新诊断SLE患者TE风险升高需要关注并尽早采取预防策略,尤其aPL阳性患者在SLE诊断前后风险突出。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This population-based study aimed to determine timing and incidence of arterial and venous thromboembolic events (TE) and antiphospholipid syndrome (APS) relative to systemic lupus erythematosus (SLE) onset and assess relationships between TE, APS and anti-phospholipid antibodies (aPL) during follow-up. METHODS: We included all medical-record confirmed new-onset SLE patients in Southeast Norway (population 2.9 million) 2000-2017 who fulfilled the 2019 European Alliance of Rheumatology Associations/American College of Rheumatology classification criteria. APS was defined by the 2006 Sydney classification criteria, and aPL positivity was determined following international guidelines. Key outcomes were APS, TE and death. We estimated outcome-free survival using Kaplan-Meier methods. RESULTS: Among 700 new-onset SLE patients followed for a mean of 8 years (SD 5.0), 13% (89/700) experienced a new TE. TE incidence peaked at 59 per 100 person-years (95% CI 38 to 87) in the first year of SLE among aPL positive patients diagnosed with APS, falling to 12 (95% CI 6.2 to 21) in the subsequent 4 years. In patients without APS, corresponding TE incidences were 2.6 (95% CI 1.4 to 4.3) and 0.9 (95% CI 0.5 to 1.4), respectively. The lowest TE incidence was in aPL-negative patients aged <50 years, with 1-year TE-free survival of 0.99 (95% CI 0.97 to 1.0). Beyond the first year, TE-free survival rates did not differ between SLE patients positive and negative for aPL. Standardised mortality rate in patients with and without APS was 4.7 (95% CI 1.8 to 10.7 and 1.7 (95% CI 1.2 to 2.3). CONCLUSIONS: This population-level study reveals high risk of TE, particularly for aPL positive patients around the time of SLE diagnosis. The elevated TE risk requires attention and early preventive strategies in newly diagnosed SLE.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Moe SR, Haukeland H, Brunborg C, et al. Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study. RMD Open. 2025. PMID: 40903053. doi:10.1136/rmdopen-2025-005795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。